V
Vitruvias Therapeutics
Vitruvias Therapeutics focuses on developing niche topical generic products that are sold only by prescription
About Vitruvias Therapeutics
Vitruvias Therapeutics is a specialized pharmaceutical company that partners with small global firms to bring international generic products to the U.S. market. The company operates primarily in the generic pharmaceutical sector, focusing on products that are difficult to formulate and manufacture but meet essential healthcare needs. Vitruvias leverages its deep industry expertise and extensive knowledge of U.S. regulatory processes to help its partners successfully navigate the complexities of the American market. The business model revolves around strategic partnerships, long-term relationships, and ethical practices, ensuring that both parties benefit from the collaboration. Vitruvias generates revenue through these partnerships by sharing in the profits from the sale of the generic products in the U.S. market. The company's clients include small to mid-sized pharmaceutical firms looking to expand their market reach into the United States.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2018 | $12M | $46M | Perceptive Advisors · JW Asset Management | — |
| SEED✓Equity / VC | Aug 2014 | $200K | $800K | Undisclosed | — |
Growth signals
Latest recorded traffic for Vitruvias Therapeutics is 1.7K monthly website visits, up 54.5% over the last three months. Vitruvias Therapeutics's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vitruvias Therapeutics in the Auburn ecosystem
The Vitruvias Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Perceptive Advisors
JW Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vitruvias Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vitruvias Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










